1 |
Ana001xhcl (syntagon) or vexa-04 (patheon) |
- |
- |
- |
- |
156 [1] 156 💬 |
2 |
Behavioral: clinical characteristics of ams patients |
- |
- |
- |
- |
017 [1] 17 💬 |
3 |
Behavioral: pat sessions |
- |
- |
- |
- |
006 [1] 6 💬 |
4 |
Behavioral: physical activity together for pwms and their cgs (pat-ms) |
- |
- |
- |
- |
013 [1] 13 💬 |
5 |
Biil 284 bs, high dose, adult patients |
- |
- |
- |
- |
299 [1] 299 💬 |
6 |
Biil 284 bs, high dose, pediatric patients |
- |
- |
- |
- |
299 [1] 299 💬 |
7 |
Biil 284 bs, low dose, adult patients |
- |
- |
- |
- |
299 [1] 299 💬 |
8 |
Biil 284 bs, low dose, pediatric patients |
- |
- |
- |
- |
299 [1] 299 💬 |
9 |
Biil 284 bs, medium dose, adult patients |
- |
- |
- |
- |
299 [1] 299 💬 |
10 |
Biil 284 bs, medium dose, pediatric patients |
- |
- |
- |
- |
299 [1] 299 💬 |
11 |
Buprenorphine transdermal patch |
Buprenorphine |
[2] D00836 D00836, D07132 D07132 💬 |
OPRK1 [2] OPRK1, OPRM1 💬 |
Estrogen signaling pathway [3] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
046 [1] 46 💬 |
12 |
Cell-based therapy of autologous adipose derived regenerative cells transplanted intraspinally and intrathecally in als patients |
- |
- |
- |
- |
002 [1] 2 💬 |
13 |
Cf patients with a g551d mutation and treated with ivacaftor |
Ivacaftor |
[1] D09916 D09916 💬 |
CFTR [1] CFTR 💬 |
ABC transporters [8] ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway |
299 [1] 299 💬 |
14 |
Cryopreserved efs-ada lv transduced patient cd34+ cells |
- |
- |
- |
- |
065 [1] 65 💬 |
15 |
Cryopreserved g2scid lentiviral vector transduced patient cd34+ cells |
- |
- |
- |
- |
065 [1] 65 💬 |
16 |
Device: smartpill motility system & pillcam patency capsule |
- |
- |
- |
- |
299 [1] 299 💬 |
17 |
Diagnostic test: blood drawing in patients with was |
- |
- |
- |
- |
065 [1] 65 💬 |
18 |
Dietary supplement for pku patients |
- |
- |
- |
- |
240 [1] 240 💬 |
19 |
Ef1as-ada lentiviral vector transduced patient cd34+ cells |
- |
- |
- |
- |
065 [1] 65 💬 |
20 |
Etims (edc-fixed autologous pbmcs coupled with 7 immunodominant myelin peptides in ms patients) |
- |
- |
- |
- |
013 [1] 13 💬 |
21 |
Ex vivo culture and transduction of the patient's autologous cd34+ hsc with lentivirus vector vsv-g pseudotyped cl20- 4i-ef1a-hyc-opt vector |
- |
- |
- |
- |
065 [1] 65 💬 |
22 |
Exelon 4.6 mg/24 h transdermal patch |
- |
- |
- |
- |
006 [1] 6 💬 |
23 |
Exelon 9.5 mg/24 h transdermal patch |
- |
- |
- |
- |
006 [1] 6 💬 |
24 |
Exelon patch |
- |
- |
- |
- |
006 [1] 6 💬 |
25 |
Exelon patch (rivastigmine transdermal system) |
Rivastigmine |
[2] D02558 D02558, D03822 D03822 💬 |
ACHE [1] ACHE 💬 |
Cholinergic synapse [2] Cholinergic synapse, Glycerophospholipid metabolism |
006 [1] 6 💬 |
26 |
Exelon path transdermal |
- |
- |
- |
- |
006 [1] 6 💬 |
27 |
Fentanyl transdermal patch |
Fentanyl |
[2] D00320 D00320, D01399 D01399 💬 |
OPRM1 [1] OPRM1 💬 |
Estrogen signaling pathway [3] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
046 [1] 46 💬 |
28 |
Gamma-secretase/notch signalling pathway inhibitor ro4929097 |
- |
- |
- |
- |
074 [1] 74 💬 |
29 |
Golimumab 50 mg in patients <80 kg and golimumab 100 mg in patients >80 kg |
Golimumab |
[1] D04358 D04358 💬 |
TNF [1] TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications [65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
097 [1] 97 💬 |
30 |
Growth hormone replacement therapy in growth hormone deficient patients only. |
Somatotropin |
[1] D02691 D02691 💬 |
GHR [1] GHR 💬 |
Cytokine-cytokine receptor interaction [5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
078 [1] 78 💬 |
31 |
Hp-3000 (ropinirole hydrochloride patch) |
Ropinirole |
[2] D00784 D00784, D08489 D08489 💬 |
DRD2 [3] DRD2, DRD3, DRD4 💬 |
Alcoholism [8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 [1] 6 💬 |
32 |
Hp-3000(ropinirole hydrochloride patch) |
Ropinirole |
[2] D00784 D00784, D08489 D08489 💬 |
DRD2 [3] DRD2, DRD3, DRD4 💬 |
Alcoholism [8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 [1] 6 💬 |
33 |
Intervention for incipient patients at low risk of disease progression |
- |
- |
- |
- |
066 [1] 66 💬 |
34 |
Intervention for patients at high risk of disease progression |
- |
- |
- |
- |
066 [1] 66 💬 |
35 |
Lidocaine patch 5% |
Lidocaine |
[3] D00358 D00358, D02086 D02086, D08127 D08127 💬 |
SCN1A [5] SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes [3] Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
013 [1] 13 💬 |
36 |
Long term follow up in all patients who received sar422459 in previous study tdu13583 |
- |
- |
- |
- |
301 [1] 301 💬 |
37 |
Loxoprofen sodium hydrogel patch |
Loxoprofen |
[1] D08149 D08149 💬 |
PTGS1 [2] PTGS1, PTGS2 💬 |
Alzheimer disease [23] Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
271 [1] 271 💬 |
38 |
Neupro 2 mg/24 h transdermal patch |
- |
- |
- |
- |
006 [1] 6 💬 |
39 |
Neupro 2mg/24 h transdermal patch |
- |
- |
- |
- |
006 [1] 6 💬 |
40 |
Neupro 2mg/24h transdermal patch |
- |
- |
- |
- |
006 [1] 6 💬 |
41 |
Neupro 4 mg/24 h transdermal patch |
- |
- |
- |
- |
006 [1] 6 💬 |
42 |
Neupro 4mg/24 h transdermal patch |
- |
- |
- |
- |
006 [1] 6 💬 |
43 |
Neupro 4mg/24h transdermal patch |
- |
- |
- |
- |
006 [1] 6 💬 |
44 |
Neupro 4mg/24hr transdermal patch |
- |
- |
- |
- |
006 [1] 6 💬 |
45 |
Neupro 6 mg/24 h transdermal patch |
- |
- |
- |
- |
006 [1] 6 💬 |
46 |
Neupro 6mg/24 h transdermal patch |
- |
- |
- |
- |
006 [1] 6 💬 |
47 |
Neupro 6mg/24h transdermal patch |
- |
- |
- |
- |
006 [1] 6 💬 |
48 |
Neupro 8 mg/24 h transdermal patch |
- |
- |
- |
- |
006 [1] 6 💬 |
49 |
Neupro 8mg/24h transdermal patch |
- |
- |
- |
- |
006 [1] 6 💬 |
50 |
Nicotine patch |
Nicotine |
[3] D03365 D03365, D05156 D05156, D05157 D05157 💬 |
CHRNA1 [16] CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 |
Alzheimer disease [7] Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases |
006 [2] 6 , 84 💬 |
51 |
Nicotine transdermal patch |
Nicotine |
[3] D03365 D03365, D05156 D05156, D05157 D05157 💬 |
CHRNA1 [16] CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 |
Alzheimer disease [7] Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases |
006 [1] 6 💬 |
52 |
Observational study with patients treated with tracleer, ventavis, veletri, opsumit and/or uptravi |
- |
- |
- |
- |
086 [1] 86 💬 |
53 |
Other: histone acetylation profiles of cells of srt patients with crebbp mutations |
- |
- |
- |
- |
102 [1] 102 💬 |
54 |
Other: neupro 4 mg / 24 hr. transdermal patch |
- |
- |
- |
- |
006 [1] 6 💬 |
55 |
Other: observation of ocrelizumab as treatment in rrms patients |
Ocrelizumab |
[1] D05218 D05218 💬 |
MS4A1 [1] MS4A1 💬 |
Hematopoietic cell lineage [1] Hematopoietic cell lineage |
013 [1] 13 💬 |
56 |
Other: the patients' parents have to complete the vineland ii adaptive behavior scales scoring, the sleep disturbance scale for children (sdsc) and horne & ostberg circadian typology questionnaire |
- |
- |
- |
- |
149 [1] 149 💬 |
57 |
Other: transthoracic echocardiography at rest, during plr, hg and cpx (including blood gas analysis in both groups). additionally fallot patients will undergo routine blood testings. |
- |
- |
- |
- |
215 [1] 215 💬 |
58 |
Oxycodone by patient-controlled analgesia (pca) |
Oxycodone |
[3] D03783 D03783, D05312 D05312, D05462 D05462 💬 |
OPRD1 [3] OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway [5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
046 [1] 46 💬 |
59 |
Pat |
- |
- |
- |
- |
006 [3] 6 , 13, 160 💬 |
60 |
Pat-001, 0.1% |
- |
- |
- |
- |
160 [1] 160 💬 |
61 |
Pat-001, 0.2% |
- |
- |
- |
- |
160 [1] 160 💬 |
62 |
Patient current care |
- |
- |
- |
- |
046 [1] 46 💬 |
63 |
Patient treated with dmard |
- |
- |
- |
- |
046 [1] 46 💬 |
64 |
Patients will be randomized to receive ehp-101 |
- |
- |
- |
- |
051 [1] 51 💬 |
65 |
Patients' existing non-steroidal anti-inflammatory drug (nsaid) at approved doses |
- |
- |
- |
- |
046 [1] 46 💬 |
66 |
Pd patients h&y=1.5-2 medications off |
- |
- |
- |
- |
006 [1] 6 💬 |
67 |
Pd patients h&y=1.5-2 medications on |
- |
- |
- |
- |
006 [1] 6 💬 |
68 |
Pd patients h&y=3 medications off |
- |
- |
- |
- |
006 [1] 6 💬 |
69 |
Pd patients h&y=3 medications on |
- |
- |
- |
- |
006 [1] 6 💬 |
70 |
Procedure: skin biopsy for the primary fibroblast culture and a 15 ml blood sample (3 unnamed samples of 5ml) in each of the 4 srt patients included. |
- |
- |
- |
- |
102 [1] 102 💬 |
71 |
Procedure: speech pathology evaluation |
- |
- |
- |
- |
078 [1] 78 💬 |
72 |
Procedure: tof repair with trans-annular patch vs preservation of pv |
- |
- |
- |
- |
215 [1] 215 💬 |
73 |
Procedure: use of an electronic data capture system by patients and physicians to assess patient-physician interactions & therapeutic decisions & outcomes in ra subjects. |
Bifenthrin |
- |
- |
- |
046 [1] 46 💬 |
74 |
Rituximab, observational study amon patients with active ra |
Rituximab |
[1] D02994 D02994 💬 |
MS4A1 [1] MS4A1 💬 |
Hematopoietic cell lineage [1] Hematopoietic cell lineage |
046 [1] 46 💬 |
75 |
Rivastigmin luye transdermal patches - 4.6mg/24h |
- |
- |
- |
- |
006 [1] 6 💬 |
76 |
Rivastigmine luye transdermal patch- 9.5mg/24h |
Rivastigmine |
[2] D02558 D02558, D03822 D03822 💬 |
ACHE [1] ACHE 💬 |
Cholinergic synapse [2] Cholinergic synapse, Glycerophospholipid metabolism |
006 [1] 6 💬 |
77 |
Rivastigmine patch 9.5 cm2 |
Rivastigmine |
[2] D02558 D02558, D03822 D03822 💬 |
ACHE [1] ACHE 💬 |
Cholinergic synapse [2] Cholinergic synapse, Glycerophospholipid metabolism |
006 [1] 6 💬 |
78 |
Rivastigmine transdermal patch |
Rivastigmine |
[2] D02558 D02558, D03822 D03822 💬 |
ACHE [1] ACHE 💬 |
Cholinergic synapse [2] Cholinergic synapse, Glycerophospholipid metabolism |
006 [2] 6 , 13 💬 |
79 |
Rotigotine transdermal patch |
Rotigotine |
[1] D05768 D05768 💬 |
DRD2 [1] DRD2 💬 |
Alcoholism [8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 [1] 6 💬 |
80 |
Rotigotine transdermal patch 2mg/24h(10cm2) |
Rotigotine |
[1] D05768 D05768 💬 |
DRD2 [1] DRD2 💬 |
Alcoholism [8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 [1] 6 💬 |
81 |
Rotigotine transdermal patch 4mg/24h (20cm2) |
Rotigotine |
[1] D05768 D05768 💬 |
DRD2 [1] DRD2 💬 |
Alcoholism [8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 [1] 6 💬 |
82 |
Rotigotine transdermal patch 6mg/24h (30cm2) |
Rotigotine |
[1] D05768 D05768 💬 |
DRD2 [1] DRD2 💬 |
Alcoholism [8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 [1] 6 💬 |
83 |
Rotigotine transdermal patch 8mg/24h (40cm2) |
Rotigotine |
[1] D05768 D05768 💬 |
DRD2 [1] DRD2 💬 |
Alcoholism [8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 [1] 6 💬 |
84 |
Routine transdermal oestrogen patch |
- |
- |
- |
- |
078 [1] 78 💬 |
85 |
The effectiveness of xeljanz in rheumatoid arthritis patients |
- |
- |
- |
- |
046 [1] 46 💬 |
86 |
Tnf-blockers suspension in patients with rheumatoid arthritis |
- |
- |
- |
- |
046 [1] 46 💬 |
87 |
Transduced patient cd34+ cells |
- |
- |
- |
- |
065 [1] 65 💬 |
88 |
Treat with lansoprazole 30 mg bid for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms |
Lansoprazole |
[1] D00355 D00355 💬 |
ATP4A [2] ATP4A, ATP4B 💬 |
Collecting duct acid secretion [4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
098 [1] 98 💬 |